Abstract 14669: Prevalence of Elevated Lp(a) Levels in 629,858 Subjects From a Referral Laboratory Population in the United States

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Justin White ◽  
Steve Varvel ◽  
Sotirios Tsimikas
Keyword(s):  
United States ◽  
Cardiovascular Disease ◽  
Risk Factor ◽  
Antisense Oligonucleotides ◽  
Independent Risk Factor ◽  
The United States ◽  
Large Datasets ◽  
Laboratory Population ◽  
Diagnostic Laboratory ◽  
The Mean

Background: Elevated Lp(a) is now accepted as a causal, independent risk factor for cardiovascular disease. Data suggest that ~20% of subjects living in the Copenhagen area have elevated Lp(a) levels (>50 mg/dL. Lp(a) <50 mg/dL has been recommended as a desirable level, but similar large datasets in varied populations have not been available from other countries. Methods: We analyzed fasting Lp(a) in 629,858 subjects from the large referral dataset from Health Diagnostic Laboratory measured in years 2010 to 2014 to assess prevalence of elevated Lp(a). Lp(a) mass levels were measured by immunoturbidometric assay and expressed as mg/dL. Results: Median age of the subjects was 56, and 53.7% were female. Lp(a) levels were skewed rightward (Figure). The mean±SD levels were 31±38 mg/dL and median (IQR) levels were 15 (7-43) mg/dL, with range 0-571 mg/dL. Females had higher median (IQR) Lp(a) levels than males [16 (8-47) vs. 13 (6-38), p<0.0001]. Lp(a) percentile levels at 75%, 80%, 90%, 95% and 99% were >43 mg/dL, >55 mg/dL, >85 mg/dL, >109 mg/dL, and >169 mg/dL, respectively. Lp(a) levels >30 mg/dL and >50 mg/dL were present in 31.8% and 21.8% of subjects, respectively Conclusion: This is the largest database to assess the distribution of Lp(a). Lp(a) levels >30 and >50 mg/dL were common, constituting 31.8% and 21.8% of this referral laboratory population, and are consistent with the Copenhagen data. These data will help to define new global guidelines and therapeutic targets for new Lp(a) lowering therapies, such as antisense oligonucleotides directed to apo(a).

scholarly journals Obesity and Cancer: 27-Hydroxycholesterol, the Missing Link

2020 ◽  
Vol 21 (14) ◽  
pp. 4822
Author(s):  
Arvand Asghari ◽  
Michihisa Umetani
Keyword(s):  
United States ◽  
Cardiovascular Disease ◽  
Estrogen Receptor ◽  
Risk Factor ◽  
Cause Of Death ◽  
The United States ◽  
Missing Link ◽  
Receptor Modulator ◽  
Obesity And Cancer

Obesity is currently affecting more than 40% of the Americans, and if it progresses with this rate, soon one out of two Americans will be obese. Obesity is an important risk factor for several disorders including cardiovascular disease, the first cause of death in the United States. Cancer follows as the second deadliest disease, and a link between obesity and cancer has been suggested. However, it is very hard to establish an exact connection between obesity and cancers due to the multifactorial nature of obesity. Hypercholesterolemia is a comorbidity of obesity and also linked to several cancers. Recently a cholesterol metabolite 27-hydroxycholesterol (27HC) was found to be an endogenous selective estrogen receptor modulator (SERM), which opened new doors toward several interesting studies on the role of this molecule in biological disorders. It is speculated that 27HC might be the missing link in the obesity and cancer chain. Here, we explored the effects of 27-hydroxycholesterol on obesity and cancers with a focus on the SERM capacity of 27HC.

Identifying Properties for an Aortic Stent-Graft That Counteracts Hypertension

2018 ◽  
Author(s):  
Shannen B. Kizilski ◽  
Omid Amili ◽  
Filippo Coletti ◽  
Rumi Faizer ◽  
Victor H. Barocas
Keyword(s):  
United States ◽  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Risk Factor ◽  
Stent Graft ◽  
American Heart Association ◽  
American Heart ◽  
Heart Association ◽  
The United States ◽  
Aortic Stent Graft

In 2017, the American Heart Association reported that one third of deaths in the United States, and 31% of deaths worldwide, are attributed to cardiovascular disease (CVD) [1]. A risk factor pervasive across most types of CVD is chronic high blood pressure, or hypertension [2].

scholarly journals Aspirin for primary prevention of cardiovaascular events: what are the evidances?

2019 ◽  
Vol 38 (3) ◽  
pp. 145
Author(s):  
Yenny Yenny
Keyword(s):  
Public Health ◽  
United States ◽  
Cardiovascular Disease ◽  
Risk Factor ◽  
Primary Prevention ◽  
Cardiovascular Events ◽  
The United States ◽  
The Public

Cardiovascular disease (CVD) is the leading cause of mortality in the United States, accounting for about 1 in 3 deaths.(1) In view of the healthcare and economic burdens of cardiovascular disease, the public health aim should be the prevention of cardiovascular events through risk factor optimization.

scholarly journals Exploring Armenian Ethnicity as an Independent Risk Factor for Cardiovascular Disease: Findings from a Prospective Cohort of Patients in a County Hospital

2020 ◽  
Vol 9 ◽  
pp. 204800402095685
Author(s):  
Ara H Rostomian ◽  
Jonathan Soverow ◽  
Daniel R Sanchez
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Los Angeles ◽  
Cardiovascular Risk Factors ◽  
Prospective Cohort ◽  
Independent Risk Factor ◽  
The United States ◽  
County Hospital

Objectives While several studies have examined the risk of cardiovascular disease (CVD) in larger racial and ethnic groups within the United States, limited information is available on smaller sub-populations, such as Armenians, with high rates of CVD in their home country. This study examined the association between Armenian ethnicity and a positive exercise treadmill test (ETT). Design Prospective cohort study of patients at a 377-bed county hospital in Los Angeles, California from 2008–2011. Setting All patients were interviewed at the time of ETT to assess their cardiovascular risk factors at the cardiac laboratory of the hospital. Participants 5,006 patients between 18–89 years of age, of whom 12.6% were of Armenian ethnicity and 54.4% were female. Main Outcome Measure: ETT results as a proxy for CVD risk. Results After adjusting for cardiovascular risk factors, Armenian ethnicity was significantly associated with higher odds of positive ETT (OR = 1.40, p = 0.01). Known coronary artery disease CAD (OR = 2.28, p < 0.01), hyperlipidemia (OR = 1.37, p < 0.01), and hypertension (OR = 1.24, p = 0.05) were significantly associated with higher odds of a positive ETT. In subgroup analyses, hyperlipidemia was the only significant predictor of positive ETT (OR = 1.92, p = 0.02) among Armenians, while patient history of CAD (OR = 2.49, p < 0.01), hyperlipidemia (OR = 1.29, p = 0.03), and age (OR = 1.04, p < 0.01) were significant predictors among non-Armenians. Armenian ethnicity remained associated with higher odds of positive ETT (OR = 1.40, p < 0.01) when patients with CAD were excluded. Conclusion Armenian ethnicity may be an independent risk factor for CVD, influenced by the uniformity of the genetic pool and cultural and dietary exposures.

Sign in / Sign up

Export Citation Format

Share Document